01:12 , Jun 16, 2018 |  BioCentury  |  Finance

No easy way up

A prolonged period of underperformance at Allergan plc (NYSE:AGN) has activists agitating for change, but there likely aren’t any quick fixes. Looming competition and IP setbacks for key franchises, a mixed business development record and...
20:02 , Aug 18, 2017 |  BC Week In Review  |  Clinical News

Valeant expects to resolve manufacturing issues after second Vyzulta CRL

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said that the CGMP inspection issues identified at its Bausch + Lomb manufacturing facility in Tampa, Fla., will soon be “satisfactorily resolved.” Earlier this month, Valeant received a second...
23:45 , Aug 16, 2017 |  BC Extra  |  Company News

Valeant expects to resolve manufacturing issues

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said late Wednesday that the CGMP inspection issues identified at its Bausch + Lomb manufacturing facility in Tampa, Fla., will soon be “satisfactorily resolved.” Earlier this month, Valeant received...
16:08 , Aug 11, 2017 |  BC Week In Review  |  Clinical News

Valeant gets second CRL for Vyzulta

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said FDA issued a second complete response letter for Vyzulta latanoprostene bunod to reduce intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Valeant said the CRL...
01:10 , Aug 9, 2017 |  BC Extra  |  Company News

Aerie falls on third-party manufacturing concerns

Aerie Pharmaceuticals Inc. (NASDAQ:AERI) lost $4.45 to $51.65 on Tuesday as investors feared unresolved contract manufacturing issues could derail Aerie’s resubmitted NDA for Rhopressa netarsudil 0.02% to treat intraocular pressure (IOP) in patients with glaucoma...
01:29 , Feb 25, 2017 |  BioCentury  |  Finance

Left holding the Opdivo bag

Even though activist investors are turning up the heat a few degrees on Bristol-Myers Squibb Co. (NYSE:BMY), buysiders contacted by BioCentury view a takeout as unlikely even though the pharma has shed more than $35...
01:23 , Feb 22, 2017 |  BC Extra  |  Company News

BMS gains on investment rumors

Bristol-Myers Squibb Co. (NYSE:BMY) declined to comment on media reports that activist investor Carl Icahn has taken a stake in the company. The rumors drove BMS shares as high as $56.79 during the day on...
07:00 , Aug 1, 2016 |  BC Week In Review  |  Clinical News

Vesneo latanoprostene bunod regulatory update

FDA issued a complete response letter to Valeant for Vesneo latanoprostene bunod to treat open-angle glaucoma or intraocular pressure. Valeant said FDA’s concerns arose following an inspection of a U.S. manufacturing facility and were not...
07:00 , Jul 22, 2016 |  BC Extra  |  Company News

FDA rejects Valeant's Vesneo

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) received an FDA complete response letter for Vesneo latanoprostene bunod to treat open-angle glaucoma or intraocular pressure. Nicox S.A. (Euronext:COX), which has co-promotion rights to the candidate, fell EUR...
01:36 , Nov 5, 2015 |  BC Extra  |  Company News

Allergan strikes dry eye deal with Mimetogen

Allergan plc (NYSE:AGN) reported 3Q15 earnings and licensed dry eye candidate tavilermide ( MIM-D3 ) from Mimetogen Pharmaceuticals Inc. (Montreal, Quebec). Allergan did not give an update regarding merger talks with Pfizer Inc. (NYSE:PFE), which...